» Articles » PMID: 37175521

T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms

Abstract

Castleman disease (CD) is a rare lymphoproliferative disorder that includes various clinico-pathological subtypes. According to clinical course, CD is divided into unicentric CD (UCD) and multicentric CD (MCD). MCD is further distinguished based on the etiological driver in herpes virus-8-related MCD (that can occur in the setting of HIV); in MCD associated with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes); and idiopathic MCD (iMCD). The latter can also be divided in iMCD-TAFRO (thrombocytopenia, anasarca, fever, myelofibrosis, organomegaly) and iMCD not otherwise specified. To date, CD pathogenesis is still uncertain, but CD may represent the histological and clinical result of heterogeneous pathomechanisms. Transcriptome investigations in CD lymph nodes have documented the expression and up-regulation of different cytokines; furthermore, few recent studies have shown alterations of different T-cell subsets in CD patients, suggesting a possible role of the nodal microenvironment in CD development. On this basis, our study aimed to investigate the distribution of T-cell subsets in the clinico-pathological spectrum of CD. We evaluated the CD4/CD8 ratio and the number of T-regulatory (T-reg) FOXP3+ cells in 28 CD cases. In total, 32% of cases showed a decreased CD4/CD8 ratio due to increased CD8+ T-cells, including both UCD, iMCD, and HHV8+ MCD cases. The T-reg subset analysis revealed a statistically significant ( < 0.0001) lower mean number of FOXP3+ T-reg cells in CD cases when compared with non-specific reactive lymph nodes. We did not find statistically significant differences in T-reg numbers between the different CD subtypes. These findings may suggest that alterations in T-cell subpopulations that can lead to disruption of immune system control may contribute to the numerous changes in different cellular compartments that characterize CD.

Citing Articles

Interleukin-6 transcripts up-regulation in lymph nodes from unicentric and multicentric Castleman disease.

Lucioni M, Morello G, Cristinelli C, Fraticelli S, Neri G, Travaglino E EJHaem. 2024; 5(6):1182-1189.

PMID: 39691263 PMC: 11647691. DOI: 10.1002/jha2.1034.


scRNA-seq reveals the landscape of immune repertoire of PBMNCs in iMCD.

Yin X, Liu Y, Lv Z, Ding S, Ma L, Yang M Oncogene. 2024; 43(37):2795-2805.

PMID: 39147879 DOI: 10.1038/s41388-024-03128-8.


Biomarkers and Signaling Pathways Implicated in the Pathogenesis of Idiopathic Multicentric Castleman Disease/Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly (TAFRO) Syndrome.

Sumiyoshi R, Koga T, Kawakami A Biomedicines. 2024; 12(6).

PMID: 38927348 PMC: 11200392. DOI: 10.3390/biomedicines12061141.

References
1.
Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

2.
Dupin N, Diss T, Kellam P, Tulliez M, Du M, Sicard D . HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000; 95(4):1406-12. View

3.
Medina E, Fuehrer N, Miller F, Kinney M, Higgins R . Dysplastic follicular dendritic cells in hyaline-vascular Castleman disease: a rare occurrence creating diagnostic difficulty. Pathol Int. 2016; 66(9):535-9. DOI: 10.1111/pin.12446. View

4.
Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z . Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006; 212:8-27. DOI: 10.1111/j.0105-2896.2006.00427.x. View

5.
Wu D, Lim M, Jaffe E . Pathology of Castleman Disease. Hematol Oncol Clin North Am. 2017; 32(1):37-52. DOI: 10.1016/j.hoc.2017.09.004. View